ArticleInternational journal of radiation oncology, biology, physics2014
Uveal melanoma treated with iodine-125 episcleral plaque: an analysis of dose on disease control and visual outcomes.
Article in International journal of radiation oncology, biology, physics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 71 citations in OpenAlex.
- Comparing efficacy of charged-particle therapy with brachytherapy in treatment of uveal melanoma.Eye (London, England) · 2024Pooled it
- Efficacy and safety of carbon-ion radiotherapy for the malignant melanoma: A systematic review.Cancer medicine · 2020Pooled it
- Percutaneous implantation of (125)iodine seeds for treatment of portal vein tumor thrombosis in hepatocellular carcinoma.Medical oncology (Northwood, London, England) · 2015Trial
- Anatomical outcome after brachytherapy with bi-nuclide (Ru-106/Iodine-125) plaques in large uveal melanomas.Radiation oncology (London, England) · 2025Article
- Functional outcome after Brachytherapy with bi-nuclide (Ru-106/Iodine-125) plaques in large uveal melanomas.Radiation oncology (London, England) · 2025Article
- Integrating single-cell omics and materials science for uveal melanoma: from mechanistic insights to precision therapeutics.Frontiers in oncology · 2025Review
- A study comparing baseline and best-corrected visual acuity after iodine-125 episcleral brachytherapy in uveal melanoma.Journal of contemporary brachytherapy · 2023Article
- Transitioning from a COMS-based plaque brachytherapy program to using eye physics plaques and plaque simulator treatment planning system: A single institutional experience.Journal of applied clinical medical physics · 2023Article
- Ocular Complications of Radiotherapy in Uveal Melanoma.Cancers · 2023Review
- Dual-source strength seed loading for eye plaque brachytherapy using eye physics eye plaques: A feasibility study.Journal of contemporary brachytherapy · 2022Article
- Choroidal Melanoma with Ultrasound-Guided Episcleral Brachytherapy: Long-Term Results and Risk of Metastasis.Ocular oncology and pathology · 2021Article
- Iatrogenic Ocular Surface Diseases Occurring during and/or after Different Treatments for Ocular Tumours.Cancers · 2021Review
- Article
- Practice Patterns for the Treatment of Uveal Melanoma with Iodine-125 Plaque Brachytherapy: Ocular Oncology Study Consortium Report 5.Ocular oncology and pathology · 2020Article
- Comparison of Iodide-125 and Ruthenium-106 Brachytherapy in the Treatment of Choroidal Melanomas.Clinical ophthalmology (Auckland, N.Z.) · 2020Article
- Analysis of local recurrence causes in uveal melanoma patients treated withJournal of contemporary brachytherapy · 2019Article
- Radiobiological doses, tumor, and treatment features influence on local control, enucleation rates, and survival after epiescleral brachytherapy. A 20-year retrospective analysis from a single-institution: part I.Journal of contemporary brachytherapy · 2018Article
- Visual outcome after posterior uveal melanoma episcleral brachytherapy including radiobiological doses.Journal of contemporary brachytherapy · 2018Article
- Iodine-125 Brachytherapy for Uveal Melanoma: A Systematic Review of Radiation Dose.Ocular oncology and pathology · 2017Review
- Low-dose brachytherapy strategies to treat uveal melanoma: is less more?Melanoma management · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 1 country.
Funding
Abstract
purposeTo investigate, in the treatment of uveal melanomas, how tumor control, radiation toxicity, and visual outcomes are affected by the radiation dose at the tumor apex. METHODS AND MATERIALS: A retrospective review was performed to evaluate patients treated for uveal melanoma with (125)I plaques between 1988 and 2010. Radiation dose is reported as dose to tumor apex and dose to 5 mm. Primary endpoints included time to local failure, distant failure, and death. Secondary endpoints included eye preservation, visual acuity, and radiation-related complications. Univariate and multivariate analyses were performed to determine associations between radiation dose and the endpoint variables.
resultsOne hundred ninety patients with sufficient data to evaluate the endpoints were included. The 5-year local control rate was 91%. The 5-year distant metastases rate was 10%. The 5-year overall survival rate was 84%. There were no differences in outcome (local control, distant metastases, overall survival) when dose was stratified by apex dose quartile (<69 Gy, 69-81 Gy, 81-89 Gy, >89 Gy). However, increasing apex dose and dose to 5-mm depth were correlated with greater visual acuity loss (P=.02, P=.0006), worse final visual acuity (P=.02, P<.0001), and radiation complications (P<.0001, P=.0009). In addition, enucleation rates were worse with increasing quartiles of dose to 5 mm (P=.0001).
conclusionsDoses at least as low as 69 Gy prescribed to the tumor apex achieve rates of local control, distant metastasis-free survival, and overall survival that are similar to radiation doses of 85 Gy to the tumor apex, but with improved visual outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.